Year: 2026
Type: review
Abstract: antioxidant nanoparticles, microfluidic sperm selection and improved cryopreservation-to targeted therapies for complex disorders including premature ovarian insufficiency, polycystic ovary syndrome, and endometriosis. Despite promising preclinical outcomes, clinical translation is impeded by challenges regarding biocompatibility, large-scale manufacturing, and ethical regulation. Future perspectives emphasize the integration of multi-omics, artificial intelligence, and biocompatible material innovation to elucidate molecular mechanisms and accelerate the transition from bench to bedside, ultimately advancing precision reproductive medicine.
Source: RSC Advances
DOI: 10.1039/d6ra01614f
Authors: Xu Wen(Conceptualization, Formal analysis, Investigation, Writing – original draft), Zhiyan Wang, Jiahui Lin(Data curation, Validation, Visualization), Longjie Li, Haiyun Wang(Validation), Pei Liu(Investigation), Hao Hu(Visualization), Chao He(Resources), Zijia Zheng(Data curation), Ruisi Liu(Investigation), Kejun Dong(Methodology, Writing – review & editing), Donghui Huang(Methodology, Writing – review & editing), Xianjin Xiao(Funding acquisition, Methodology, Resources, Supervision, Writing – review & editing)
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Keywords: nanotechnology, reproductive medicine, antioxidant nanoparticles, microfluidic sperm selection, sperm cryopreservation, targeted therapeutics, premature ovarian insufficiency, polycystic ovary syndrome, endometriosis, biocompatibility, clinical translation, multi-omics, artificial intelligence, biomaterials
Open Access status: gold
Estimated APC paid: $1,042
OpenAlex ID: W7167688841
